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ABSTRACT 
 
Integrative genomic and gene expression analyses have identified amplified oncogenes in B-cell 
non-Hodgkin lymphoma (B-NHL), but the capability of such technologies to localize tumor 
suppressor genes within homozygous deletions remains unexplored. Array-based comparative 
genomic hybridization (CGH) and gene expression microarray analysis of 48 cell lines derived 
from patients with different B-NHLs delineated twenty homozygous deletions at seven 
chromosome areas, all of which contained tumor suppressor gene targets. Further investigation 
revealed that only a fraction of primary biopsies presented inactivation of these genes by point 
mutation or intragenic deletion, but instead some of them were frequently silenced by epigenetic 
mechanisms. Notably, the pattern of genetic and epigenetic inactivation differed among B-NHL 
subtypes. Thus, the P53-inducible PIG7/LITAF was silenced by homozygous deletion in primary 
mediastinal B-cell lymphoma and by promoter hypermethylation in germinal center lymphoma, 
the pro-apoptotic BIM gene presented homozygous deletion in mantle cell lymphoma and 
promoter hypermethylation in Burkitt lymphoma, pro-apoptotic BH3-only NOXA was mutated and 
preferentially silenced in diffuse large B cell lymphoma and INK4c/P18 was silenced by bi-allelic 
mutation in mantle cell lymphoma with unmutated IGH gene. Our microarray strategy has 
identified novel candidate suppressors inactivated by genetic and epigenetic mechanisms that 
substantially vary among the B-NHL subtypes.  
 3
INTRODUCTION 
 
The B-cell non-Hodgkin lymphomas (B-NHLs) comprise various distinct clinico-pathological 
entities that in most instances are characterized by recurrent chromosomal translocations 
involving the immunoglobulin (IG) gene loci.
1
 IG chromosomal translocations are thought to be 
early events in the pathogenesis of these malignancies and result in deregulated expression of a 
variety of oncogenes involved in cell proliferation, differentiation pathways and apoptosis 
regulation. However, they are not usually sufficient for tumor formation and the accumulation of 
other genetic aberrations is critical for the acquisition of the full neoplastic phenotype.
2
 
Comparative genomic hybridization (CGH) and CGH to BAC microarray techniques have 
identified recurrent regions of amplification and deletion, many of which are predicted to encode 
oncogenes and tumor suppressor genes that are important for tumorigenesis.
3-9
 The impact of 
DNA amplification on gene expression variation has been investigated at the genome scale in 
breast cancer,
10
 lung cancer,
11
 pancreatic adenocarcinoma,
12
 and B-cell lymphoma.
13,14
 These 
and other reports led to the positional identification of over-expressed genes mapped at the 
peaks of amplification in tumor cells.
4,13,15-18
 However, the capability of array-based CGH 
combined with gene expression microarrays to carry out genome-wide screens for regions of 
deletion that may harbor putative tumor suppressor genes in B-NHL has not been explored yet. 
 
To discover tumor suppressor genes with previously unknown relevance in lymphoma that may 
be silenced by homozygous deletion, we applied high-resolution BAC array CGH and gene 
expression profiling microarrays to a panel of 48 cell lines derived from patients with the different 
B-NHL subtypes.
19,20
 We identified twenty homozygous deletions at seven different chromosome 
areas. Delineation of these loci and search for contained genes with reduced expression revealed 
known suppressor genes as well as novel putative targets that were further characterized in cell 
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lines and in primary lymphoma biopsies by FISH analysis, mutation screening and promoter 
methylation studies, quantitative real-time PCR, Western blot and immunohistochemistry on 
tissue microarrays. Our data demonstrate that array CGH combined with gene expression 
profiling provide a rationale for discovering tumor suppressor genes in regions of homozygous 
loss. These target genes show different patterns of gene inactivation that vary among the B-NHL 
subtypes. 
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MATERIAL AND METHODS 
 
TUMOR CELL LINES: A panel of forty-eight cell lines derived from patients comprising the 
various subtypes of B-NHL was studied:
 
Granta 519, HBL2, SP49, Z138, REC1, NCEB1, JVM2, 
UPN1, UPN2, SP53, JEKO1 and IRM2 (mantle cell lymphoma; n=12); OZ, VAL, Karpas 422, 
DOHH2, Karpas 353, PR1, OCI-LY8, Karpas 231, SUDHL6, ROS-50, RL, SCI1, BEVA, Granta 
452 and 380 (diffuse large B cell lymphoma with the translocation t(14;18)(q32;q21); n=15); 
MD901, MD903, RIVA, CTB1, RCK8 and CIPULLO (diffuse large B-cell lymphoma lacking 
t(14;18)(q32;q21) translocation; n=6); ELIJAH, NAB2, PL29018, SERAPHINA, Wien-133, P32, 
BALM9, CA46, Namalwa, BL41 and KHM10B (Burkitt lymphoma; n=11), SSK41 and Karpas 
1718 (marginal zone lymphoma); and Karpas 1106 and MEDB1 (primary mediastinal B-cell 
lymphoma).  
CYTOGENETIC ANALYSES. Twenty-five of the cell lines (those underlined) were studied by G-
banding cytogenetics and standard CGH to chromosomes (s-CGH). In fifteen of them showing 
complex karyotypes, additional color cytogenetic analysis including cross-species color banding 
(RxFISH, Cambio), spectral karyotyping (SKY, Applied Spectral Imaging), and/or multicolor FISH 
(SpectraVysion, Vysis), 
FLUORESCENCE IN SITU HYBRIDIZATION (FISH). To classify the cell lines into clinical-
pathological B-NHL subgroups according to the presence of chromosomal translocations and to 
confirm the DNA copy number changes obtained from array CGH studies, FISH analysis using 
individual probes was performed on fixed cells from selected cell lines. These BAC and PAC 
probes corresponded to IGH, CCND1, BCL2, BCL6, MALT1, MYC and CDK6 gene loci. In 
addition, BACs RP11-233N20 (3q29), RP11-215F02 (11p13), RP11-89M8 (8p21.3) and RP11-
165N12 (13q31.3) were also used. To further delineate the 16p13.13 genomic deletion, we also 
hybridized BACs  RP11-89D3, RP11-109M19, RP11-66H6, RP11-396B14, RP11-547D14, 
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RP1149M6, RP11-394B14, and RP11-165B11 in cells from Karpas 1106 cell line. These clones 
were purchased from Research Genetics (Huntstville, AL, USA), Vysis (Downers Grove, IL, 
USA), or RZPD German Resource Center (Berlin, Germany).  
MICROARRAY-BASED COMPARATIVE GENOMIC HYBRIDIZATION AND DATA ANALYSIS: 
Genome-wide analysis of DNA-copy number changes of the 48 cell lines was performed using 
array CGH on a microchip with ∼2.400 BAC and P1 clones in triplicate. The array provides an 
average resolution of 1.4 Mb across the genome. Production and validation of the array, 
hybridization methods and analytical procedures have been described elsewhere.
5,19
 For 
delineation of common regions of genomic imbalance in the lymphoma genomes, the position of 
the BAC/PACs on the draft human genome sequence according to the May 2004 freeze was 
used (http://genome.cse.ucsc.edu). For visualization of genomic data, the TreeView program 1.60 
(Stanford, CA) was used. Microarray data has been deposited in GEO database (GPL37898). 
GENE EXPRESSION MICROARRAY ANALYSIS: To investigate the level of expression of the 
genes mapped across the common regions of genomic gain and loss, the “Lymphochip” cDNA 
microarrays were used for the gene expression profiling of 32 of the B-NHL cell lines, as 
previously reported.
20
 In 8 mantle cell lymphoma cell lines (Granta 519, HBL2, SP49, NCEB1, 
JVM2, UPN1, JEKO1 and IRM2), Affymetrix Gene Chips Human Genome U133 microarray 
studies were also performed according to the manufacturer´s instructions.  
REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION (QRT-PCR): To validate the 
data from the cDNA microarrays for CDK6 and NOXA, the same RNA aliquots used in the cDNA 
microarray analysis were studied using QRT-PCR, as previously described.
17
 To study the 
expression levels of PIG7/LITAF and BIM, QRT-PCR was performed in an ABI PRISM 7500 
Sequence Detection System (Applied Biosystems, Weitersadt, Germany) using the Assay-on-
Demand Gene Expression product for
 
PIG7/LITAF (ABI-Hs.00191583) and BIM (ABI-
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Hs.00197982). The mRNA expression was normalized by using GAPDH gene product as 
endogenous control of expression  (ABI-Hs.99999905). 
DELINEATION OF HOMOZYGOUS DELETIONS: To confirm homozygous deletion according to 
array CGH data, PCR on genomic DNA was performed in the corresponding cell lines. Additional 
primer sets were designed and applied to further narrow down the regions of deletion. 
WESTERN BLOTTING OF CELL LINES AND PRIMARY B-NHL SAMPLES: A number of 
deregulated genes (CDK6, PIG7/LITAF, NOXA, BCL6, INK4c/P18 and BIM) were selected for 
Western blot analysis in the B-NHL cell lines and biopsies from patients with B-NHL. Cellular 
proteins were extracted with a buffer containing protease inhibitors (1% aprotinin, 2 mM of 
phenylmethylsulfonyl fluoride, and 10 µg/ml leupeptin) and a phosphatase inhibitor (2 mM of 
sodium orthovanadate). Equal amounts of protein from each sample (50 µg) were separated on 
SDS-PAGE gels, and electrotransfered to nitrocellulose membranes. Finally, membranes were 
incubated with primary antibodies followed by secondary antibodies conjugated to horseradish 
peroxidase, which was detected by chemiluminescence (Pierce, Rockford, IL). The following 
proteins were analyzed: CDK6 and PIG7/LITAF (BD Biosciences, San Diego, CA); NOXA 
(Oncogene Research Products, Boston, MA);  BIM (Stressgen, Canada); INK4c/P18 (Santa Cruz 
Biotechnology, Santa Cruz, CA, US) and BCL6 (DakoCytomation, Denmark). To evaluate equal 
protein transfer, detection of Actin (Oncogene Research Products, Boston, MA), β-tubulin 
(SIGMA, Saint Louis, M) or staining with Ponceau S (Sigma-Aldrich) were performed. Protein 
extracts from B-cells obtained from two non-tumoral tonsils were also analyzed.  
MUTATION ANALYSIS OF NOXA, PIG7/LITAF, INK4C/P18 AND BIM.
 
For mutational analysis 
of NOXA, genomic DNA was extracted from the 48 cell lines, biopsy samples from 106 patients 
with different B-NHL subtypes and 50 peripheral blood samples from healthy donors. Sets of 
primers were designed to amplify the coding region, including each splicing site and 650 bp of the 
promoter, which included the possible P53 response element. For mutational analysis of 
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PIG7/LITAF and BIM, the entire coding region, and each splicing site were amplified in 48 cell 
lines and 15 patients with different B-NHL subtypes. For mutational analysis of INK4c/P18, the 
coding region was analyzed in the B-NHL cell lines as well as in 20 mantle cell lymphoma 
biopsies. PCR products were directly sequenced by using an ABI 3730 Genetic Analyzer 
sequencer (Applied Biosystems). NOXA gene sequence changes in B-NHL cell lines and patient 
samples; the nucleotide positions of NOXA are based on GenBank accession sequence 
NM_021127. The nucleotide positions of PIG7/LITAF are based on GenBank accesion sequence 
NM_004862, BIM on GenBank accesion sequence NM_138621 and INK4c/P18 on GenBank 
accesion sequence NM_001262. 
METHYLATION ANALYSIS OF NOXA, INK4C/P18, PIG7/LITAF AND BIM PROMOTERS. One 
µg of genomic DNA was treated with bisulfite using the CpGenomic
TM
 DNA Modification Kit 
(Intergen Company, Purchase, NY).
 
Sequence primers for the MSP analysis were designed in 
the 5’ unstranslated region CpG island of the published sequences near translation start site. 
CpGenome Universal Methylated DNA (Serogicals Corporation) bisulfite-modified was used as a 
positive control. To evaluate demethylation, cells were treated with 4µM of the demethylating 
agent 5-aza-2´-deoxycitidine (Sigma); after incubation of 96 hours, cells were harvested for MSP, 
RT-PCR and Western blotting. For sequencing analysis, both PIG7/LITAF and BIM promoters 
were amplified by nested-PCR after bisulfite modification. Amplification products obtained in the 
second PCR reaction, were subcloned into pCR® 4-TOPO® plasmid using TOPO TA Cloning® 
Kit for Sequencing (Invitrogen Life Technologies, Paisley, UK) and transformed into Escherichia 
coli according to the manufacturer's recommendations. Colonies with recombinant plasmids 
containing the described PCR products were screened by digestion with EcoR I (Amersham 
Biosciences, Buckinghamshire, UK). Candidate plasmid clones were sequenced. Primers for 
delineation homozygous deletions, genomic sequencing, QRT-PCR, methylation specific PCR 
and sequencing after sodium bisulfite are shown in Supplemental Table S1 
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PS341 SENSITIVITY ASSAYS.  Exponentially growing cells were plated at 1 x 10
6
  cells/mL of 
RPMI medium in 24-well microtiter plates. The proteosome inhibitors PS341 (bortezomib) at 
concentrations of 10 and 100 nM and MG132 at 1000nM were added. After 6, 24 and 48 hours, 
apoptotic cells were quantified by staining with fluorescein isothiocyanate (FITC)-conjugated 
Annexin V and propidium iodide according to the manufacturer´s instructions (BD Pharmingen). 
Cell fluorescence was detected on a FACScalibur (Becton Dickinson). A minimum of 10.000 cells 
were acquired and analyzed using Cell Quest analysis software. All experiments were performed 
at least in triplicate. 
TISSUE MICROARRAY STUDY OF B-NHL PATIENT SAMPLES:
 
Pretreatment samples from 
367 patients with B-NHL were analyzed using immunohistochemistry (IHC) on tissue microarrays 
(TMA) using a Tissue Arrayer device (Beecher Instruments, MD) as previously described.
21
 
Duplicated cylinders from follicular lymphoma (72 cases), mantle cell lymphoma (103 cases), 
diffuse large B-cell lymphoma (67 cases), splenic marginal zone lymphoma (77 cases), and B-cell 
chronic lymphocytic leukemia (48 cases) were included. Antibodies for NOXA, CD10, BCL2, 
MUM1, BCL6, LITAF, INK4c/P18 and BIM were used. Informed consent was obtained from each 
subject or subject’s guardian. Human investigations were performed after approval by an 
institutional review board on scientific and ethical affairs. 
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RESULTS 
 
HIGH RESOLUTION ANALYSIS OF B-NHL GENOMES 
We performed genome-wide scanning for DNA copy number changes in 48 B-NHL cell lines 
using high-resolution array CGH (Supplemental Figure S1 and Supplemental Table S2). Eighty-
eight high-level amplification events (defined by ≥ 4 fold DNA copy number increase) were 
detected, ranging from 4 to 11 fold increase and affecting 46 different chromosomal regions 
(Supplemental Table S3). In addition to high-level amplifications, the most common regions of 
low-level genomic over-representation were detected at chromosome bands 7q21.13-q21.3 (25 of 
48 cell lines, 52%), 7q22.1 (48%), 7p11.2-p22.3 (44%), 8q24.1 (42%), 13q31.3-q32.3 (38%), 
1q21.2-q25.1 (31-33%), 12q13.13 (29%), 18q21.1-q21.32 (27%) and Xq26.3-q28 (27%). Array 
CGH delineated the most frequent heterozygous genomic losses at bands 9p21.3-p22.1 (18 of 48 
cell lines, 38%), 8p21.3 (29%), 17p13.1-p13.3 (29%), 17p13.1-q11.2 (27%), 11q24.2-q25 (25%) 
and 6q23.2-q24.1 (23%) (Supplemental Figure 2). In addition, twenty homozygous deletions 
involving seven different chromosome areas were identified (Table 1).  
 
Then we applied gene expression profiling to the cell lines and searched for genes located within 
areas of genomic aberration that presented deregulated expression. To validate our strategy, we 
sought to identify critical oncogenes known to be recurrently amplified in lymphoma, most of 
which presented convergent high-level amplification and elevated expression in the B-NHL cell 
lines.
3,4,7
 As representative examples, BCL2 at chromosome 18q21.3, BCL6 (3q27.3), REL and 
BCL11A (both in 2p16) and CDK4 (12q14.1) genes, were consistently over-expressed in cell lines 
with respective high-level amplification (Supplemental Figure S3). 
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HOMOZYGOUS DELETIONS LOCALIZE POTENTIAL TUMOR SUPPRESSOR GENES 
Next, we explored whether coupled analysis of gene expression and DNA copy number variation 
might identify candidate tumor suppressor genes by pinpointing transcripts with reduced 
expression related to homozygous losses. Array CGH detected twenty homozygous deletions 
involving seven different chromosome regions, that were confirmed by PCR analysis of BAC/PAC 
sequences and/or contained genes. These deletions ranged in size from 6 kb to 2 Mb (Table 1). 
The most frequent homozygous loss encompassed chromosome band 9p21.3 at the INK4/ARF 
locus in eight B-NHL cell lines of different origins. In the Burkitt lymphoma cell line P32, 
homozygous loss of 3p14.2 comprised the tumor suppressor gene FHIT.
22
 Both are well known 
tumor suppressor genes involved in B-NHL pathogenesis, which indicated that our strategy might 
represent a valid approach for localizing novel tumor suppressor genes. 
 
The P53-inducible gene PIG7/LITAF is silenced by homozygous deletion and promoter 
methylation in B-cell lymphoma. In the Karpas 1106 cell line derived from a patient with 
primary mediastinal B-cell lymphoma, we identified homozygous deletion of chromosome 
16p13.13. This deletion included PIG7/LITAF and SOCS1 genes, both of which showed null 
expression in the cDNA microarrays. Interestingly, bi-allelic mutation of SOCS1 was recently 
reported specifically in patients with primary mediastinal B-cell lymphoma.
23
 In addition, 
PIG7/LITAF was also considered as a candidate tumor suppressor gene, because of its P53-
inducibility and capability to regulate apoptosis.
24,25
 We performed mutational screening of 
PIG7/LITAF coding sequences in the cell lines and primary B-NHL tumors, but no pathogenic 
mutations were identified. Expression analysis of PIG7/LITAF by QRT-PCR and Western blot 
showed that PIG7/LITAF was highly expressed in non-tumoral tonsil and spleen samples, 
presenting comparable levels with mantle cell lymphoma cells, whereas its expression was much 
lower in germinal-center derived lymphomas (Figure 1A). Notably, expression of PIG7/LITAF was 
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inversely correlated with BCL6 expression in normal germinal center cells as well as in most of 
the examined cell lines at the RNA and protein levels (Figure 1B,1C,1D). A recent report 
suggested that the proto-oncogene BCL6 may repress PIG7/LITAF through the transcription 
factor MIZ-1 in germinal center B-cells.
26
 To investigate the possible pathologic mechanism 
responsible for the decreased expression of PIG7/LITAF in some lymphoma subsets, we 
analyzed promoter methylation of PIG7/LITAF. Five of 37 cell lines (14%) and 10 of 80 B-NHL 
biopsies (13%) showed promoter methylation (Figure 2A and 2B). Remarkably, PIG7/LITAF 
silencing was observed in diffuse large B cell lymphoma (9 cases) and Burkitt lymphoma (6 
cases). A detailed mapping of CpG-methylation of the promoter by bisulfite genomic sequencing 
confirmed these data (Figure 2C). Methylation of PIG7/LITAF however was not observed in 
normal B-cells from spleen, blood or tonsils (Figure 2C and data not shown). Treatment with Aza 
induced re-expression of PIG7/LITAF in methylated cell lines (Figure 2A). IHC on tissue 
microarrays from 48 patient with diffuse large B cell lymphoma biopsies confirmed the opposite 
expression of PIG7/LITAF and BCL6 in both germinal-center diffuse large B cell lymphoma (11 of 
24 cases were PIG7/LITAF- / BCL6+, 46%) and non-germinal diffuse large B cell lymphoma (10 
of 24 cases were PIG7/LITAF- / BCL6+, 42%) (Figure 1D). Our data indicate that PIG7/LITAF 
may result inactivated by promoter methylation in a subset of diffuse large B cell lymphoma and 
Burkitt lymphoma.  
 
The pro-apoptotic protein BIM is silenced by different genetic and epigenetic mechanisms 
in various B-NHL subtypes. Another region of recurrent genomic loss in 2q13-q21 containing 
BIM gene was observed in seven cell lines of different origins. Using array-based CGH, Tagawa 
et al. recently reported homozygous deletion of BIM in mantle cell lymphoma.
27
 We screened for 
homozygous deletion of BIM gene and identified five mantle-cell lymphoma cell lines (UPN1, 
SP49, SP53, JEKO1 and Z138) but also the Burkitt lymphoma cell line P32 with bi-allelic loss 
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(Figure 3A). Overall, 5 of 12 (42%) mantle cell lymphoma cell lines showed bi-allelic deletion of 
BIM. Sequencing of genomic DNA failed to identify any sequence mutation in any other cell lines 
and primary biopsies. Western blot analysis, however, showed absence of expression in a large 
proportion of lymphomas of different origins (Figure 3B). To investigate this, we determined the 
methylation status of BIM gene promoter. In 11 of 23 examined cell lines (48%) and in 7 of 26 
(27%) primary B-NHL biopsies of different origins, promoter methylation of BIM was identified. 
Methylations were more prominent in Burkitt lymphoma, where 6 of 7 cell lines examined (86%) 
and 5 of 10 patient biopsies (50%) presented BIM methylation (Figure 3C). However, this was not 
observed in any of the mantle cell lymphoma cell lines or patient biopsies studied. A detailed 
mapping of CpG-methylation of the promoter by bisulfite genomic sequencing confirmed these 
data (Figure 3D). BIM promoter methylation was correlated with loss of expression at the RNA 
and protein levels, and treatment with demethylating Aza restored BIM expression (Figure 3E). 
Immunohistochemistry (IHC) on tissue microarrays detected lack of BIM expression in 7 of 22 
MCL samples (32%) (data not shown), which is consistent with the Western blot data. In 
summary, our data indicate that BIM is frequently silenced in different B-NHL subtypes through 
various mechanisms that include homozygous deletion in mantle cell lymphoma and promoter 
methylation in Burkitt lymphoma.  
 
The INK4c/P18 gene, a member of the INK4 family of cyclin-dependent kinase inhibitors, is 
preferentially silenced in mantle cell lymphoma. In two cell lines we observed that clone 
RP11-235B24 which maps to 1p32.3 showed a genomic value close to homozygosity; further 
screen with PCR identified homozygous deletion of INK4c/P18 in two mantle cell lymphoma cell 
lines (UPN1 and HBL2) but not in the remaining B-NHL cell lines. (Figure 4A). Affymetrix 
oligonucleotide microarrays performed in MCL cell lines for genes located in 1p32.3-1p36 showed 
absence of INK4c/P18 (CDKN2C) expression in both cell lines (Figure 4B). Mutation screening 
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also identified hemizygous loss and point mutation at a critical splicing site of the remaining allele 
in JEKO1 cell line (Figure 4C). Western blot analysis revealed absence of protein expression in 
these three (UPN1, HBL2 and JEKO1) but also in most other mantle cell lymphoma cell lines, as 
well as in three patients with mantle cell lymphoma, whereas INK4c/P18 protein expression was 
observed in the majority of other B-NHL subtypes (Figure 4D). To search for other possible cause 
of decreased INK4c/P18 expression, we evaluated the promoter methylation status of INK4c/P18 
in the cell lines. These studies did not reveal any case with hypermethylation of the gene (data 
not shown). To evaluate the significance of INK4c/P18 inactivation in patients with MCL, we 
performed IHC on tissue microarrays in a clinical series of patient biopsies. INK4c/P18 was 
strongly expressed in normal B-cells including germinal center cells, but its expression was 
absent in a portion of mantle cells. In 20 of the 26 evaluable cases (77%) with available clinical 
data, INK4c/P18 expression was undetectable. Decreased INK4c/P18 expression was correlated 
with unmutated IGH status: 4 of 6 cases (67%) showing INK4c/P18 expression presented IGH 
mutation whereas only 3 of 20 cases (15%) that did not express INK4c/P18 had a mutated IGH 
gene (p=0,02) (Figure 4E)  
 
The pro-apoptotic BH3-only member of the BCL2 family NOXA is inactivated in B-NHL. In 
the Burkitt-derived cell line Elijah, a biallelic deletion of ∼1,9 Mb. in band 18q21.3 was delineated 
(Figure 5A). This loss contained the NOXA gene, a BH3-only member of the BCL2 gene family 
that showed null expression in Lymphochip microarrays.
28
 These data were confirmed by PCR on 
genomic DNA, FISH, RT-PCR and QRT-PCR. Western blot analysis showed absence of 
expression of NOXA in Elijah and Karpas 1106 cell lines, whereas very weak expression was 
observed in several other cell lines (Figure 5B). Among them, three presented loss of one copy 
as detected in array CGH experiments (Karpas 1106, UPN1 and Namalwa). The search for 
inactivating mutations of the non-deleted allele revealed mutation in two: a splice site mutation 
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58+1G→A and a silent mutation 1-35G→A in Karpas 1106, and a missense mutation 101A→G 
that resulted in the amino acid change D34G in the BH3-domain in Namalwa (Figure 5C). 
Western blot analysis revealed that 8 of 15 primary B-NHL biopsies (53%) showed very weak 
expression of NOXA. Mutational screening in patient material failed to identify any inactivating 
mutation in NOXA open reading frame but revealed three alterations in the gene promoter 
sequence: 1-752C→T (2 of 106 patients), 1-653G→A (1 of 106) and 1-576A→G (1 of 106). 
None of these alterations was found in the B-NHL cell lines or in healthy donors. In addition, 
several novel and reported polymorphisms were identified. Next we investigated NOXA protein 
expression on biopsy samples from 367 patients with B-NHL using immunohistochemistry (IHC) 
on tissue microarrays. In non-tumoral tissue samples (tonsils), NOXA was shown to be expressed 
only in a fraction of germinal center B-cells, whereas mantle, marginal and interfollicular 
lymphocytes were negative (Figure 5D). NOXA protein expression was mostly cytoplasmic, but 
also showed occasional nuclear expression. In lymphoma samples, NOXA protein expression 
was found in a subset of both diffuse large B-cell lymphoma (DLBCL) (32 of 67, 48%) and 
follicular lymphoma (20 of 103, 19%). In the remaining B-NHL subtypes, NOXA was detected in 4 
of 72 mantle cell lymphoma (5%), 4 of 77 splenic marginal zone lymphoma (5%) and 6 of 48 B-
cell chronic lymphocytic leukemia (12%) samples. In the DLBCL subgroup, patient samples were 
also evaluated for CD10, BCL2, BCL6 and MUM1 staining and thus were classified as DLBCL of 
germinal center origin (n=26) and non-germinal center DLBCL subtype (n=24). NOXA expression 
was more common in the non-germinal center subtype (58 vs. 42%; p=0,16) (Figure 5D). To 
search for other possible cause of decreased NOXA expression, we evaluated the promoter 
methylation status of NOXA in the cell lines and in the patients analyzed by Western blotting. 
These studies did not reveal any case with hypermethylation of the gene (data not shown). 
Overall, our data indicate that the reduced expression of NOXA in non-germinal center-derived 
DLBCL possibly reflects the lower expression of NOXA in the normal cell counterpart. NOXA is a 
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critical mediator of the apoptotic responses induced by P53 and other agents.
28
 Furthermore, it 
was recently reported that proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma 
and mantle cell lymphoma.
29,30
 To test this hypothesis in other B-NHL subtypes, we incubated a 
variety of B-cell lymphoma lines with and without NOXA mutation and with different levels of 
protein expression, with the proteasome inhibitor Bortezomib (PS-341). After 48 h of bortezomib 
exposure, there were no clear differences in either induction of apoptosis or apoptotic rate (Figure 
5E) in the B-NHL cell lines with or without NOXA inactivation. These data suggest that in contrast 
to previous reports, NOXA may not be of pivotal importance in triggering proteasome inhibitor-
induced apoptosis in B-cell lymphomas other than mantle cell lymphoma.
30
 
 
Novel homozygous deletion of 4q35.1 results in ARGBP2 and SNX25 truncation. Another 
region of homozygous deletion included band 4q35.1 in the Burkitt lymphoma cell line Elijah. This 
deletion was caused by the complete loss of one chromosome 4 and an interstitial deletion of the 
remaining chromosome. Delineation of the deleted segment by “PCR walking” revealed a loss of 
251 kb between two genes on chromosome 4q35.1, ARGBP2/SORBS2 centromerically and 
SNX25 telomerically (Figure 6A). The former gene encodes an adapter protein that interacts 
directly with ABL via SH3 domains in the carboxy terminus and may link ABL with the actin 
cytoskeleton.  ARGBP2 is broadly expressed in normal and malignant tissues, whereas the more 
telomeric gene, SNX25 appears to be B-cell specific. The two genes are in opposite 
transcriptional orientation. The deletion reakpoints fell within the carboxy-terminal coding regions 
of both genes; the ARGBP2 breakpoint fell within the intron immediately telomeric to exon 30, 
whilst the SNX25 breakpoint fell within an intron, centromeric to exon 15 (Figure 6B). 3’ RACE 
experiments showed splicing of both ARGBP2 and SNX25 transcripts to splice to cryptic splice 
acceptor sites and exons in the opposite transcriptional orientation, resulting in the introduction of 
premature stop codons in both genes (Figures 6C and 6D). As a consequence of the fusion, 
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ARGBP2 loses a crucial COOH terminal domain that may interfere with its binding to ABL .
31
 
However, we did not detect a similar gene fusion or a homozygous deletion in 4q35.1 in the 
remaining B-NHL cell lines nor in a subset of primary B-NHL biopsies (data not shown). The 
possible functional consequences of the truncation of the COOH terminal domain in SNX25 are 
currently unclear, and whether this novel mechanism of gene inactivation is also observed in 
other homozygous deletions in cancer is currently under investigation.  
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DISCUSSION 
 
We report that array CGH combined with gene expression profiling represents a valid strategy for 
localizing tumor suppressor genes in regions of homozygous loss in B-cell lymphoma. In a recent 
survey of homozygous deletions in 636 cancer cell lines, mostly of non-lymphoid origin,
22
 the 
gene count within homozygous deletions was low compared with the rest of the genome and 
many of these areas did not contain coding genes. In contrast, all homozygous deletions 
identified in our B-NHL cell lines included coding genes. The number of homozygous losses in 
the B-NHL cell line panel (20 in 48 cases, 0,42 per cell line) was similar to that found in the 
carcinoma cell lines (281 homozygous
 
deletions in 636 cancer cell lines, 0,44 per cell line). These 
data indicate that the integrity of the B-cell lymphoma and carcinoma genomes are equally 
unstable, but the nature of the homozygous losses may be different. In lymphoma, bi-allelic loss 
results in the inactivation of coding tumor suppressor genes probably implicated in tumor 
development and progression whereas the low density or absence of coding genes within regions 
of
 
homozygous deletion in the carcinoma cell lines raises the possibility that other types
 
of 
transcript may be the target for homozygous deletion.
22
 An attractive hypothesis is that 
homozygous deletions
 
in gene-free regions confer positive selective advantage by
 
deleting 
regulatory regions or non-coding microRNAs that are necessary for control of
 
the expression of 
recessive or dominant cancer genes.  
 
Our study pointed out several candidate tumor suppressor genes inactivated by bi-allelic deletion. 
Further investigation revealed that only a fraction of cell lines and primary biopsies presented 
inactivation of these genes by point mutation or intragenic deletion, but instead some of these 
genes were frequently silenced at the epigenetic level by promoter methylation. Notably, the 
pattern of genetic and epigenetic inactivation for these genes was different and varied among the 
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B-NHL subtypes. Thus, mantle cell lymphomas showed frequent homozygous deletion of BIM 
gene whereas it was commonly silenced by promoter methylation in Burkitt lymphoma and in 
diffuse large B-cell lymphoma. As BIM was recently reported to be the target of MYC mutants but 
not of wild-type translocated MYC in a Burkitt-lymphoma mouse model,
32
 we may speculate that 
tumor-derived MYC mutants may silence BIM expression through active recruitment of DNA 
methyltransferase corepressor, as has been reported for P21
Cip1
 gene.
33
 On the contrary, BIM 
silencing in mantle cell lymphoma seems to follow a different mechanism orchestrated by the 
cyclin D1 activation as a consequence of the t(11;14) translocation, probably in cooperation with 
the common DNA repair defects that are observed in this lymphoma subtype.
27,34
 Our data 
reinforce the role of BIM as a relatively specific suppressor of tumorigenesis inactivated through 
different mechanisms in lymphoma.
32,35
  
 
We also identified inactivation of the cyclin-dependent kinase inhibitor INK4c/P18 in MCL. 
Because unmutated IGH has been associated with aggressive clinical evolution of MCL,
36
 
inactivation of INK4c/P18 gene by bi-allelic mutation may be associated with aggressive MCL. 
We may also suggest that the decreased expression of INK4c/P18 observed in IGH-ummutated 
cells may indicate that these tumors originated from mantle cells that do not express INK4c/P18, 
whereas tumors expressing INK4c/P18 originated from IGH-mutated mantle cells that express 
INK4c/P18.  
   
One of the most prominent candidate tumor suppressor genes detected in our study is 
PIG7/LITAF, a P53 inducible gene that is also a LPS-induced TNF-alpha transcription factor.
24,25
 
In addition, mutations of PIG7/LITAF have been reported as the causative mechanism of 
Charcot-marie-Tooth disease type 1C.
37
 However, mutation screening of PIG7/LITAF coding 
sequences in the B-NHL cell lines and primary B-NHL tumors did not identify any clear 
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pathogenic mutation. The possible implication of PIG7/LITAF as a suppressor gene could be 
related to its P53-inducibility and regulation of apoptosis. Additional support for the involvement of 
PIG7/LITAF in lymphoma comes from a recent report that suggested that the proto-oncogene 
BCL6 may repress PIG7/LITAF through the transcription factor MIZ-1 in germinal B-cells.
26
 
Supporting this hypothesis, we have observed an inverse correlation of PIG7/LITAF and BCL6 
expression in most of the examined cell lines at the RNA and protein levels. Our data strongly 
suggest that PIG7/LITAF may have suppressor activity in diffuse large B-cell lymphoma and 
Burkitt lymphoma. We hypothesize that mutant BCL6 may silence PIG7/LITAF by inducing its 
promoter methylation. The cell lines described here are being used to functionally characterize 
PIG7/LITAF and its role in B-cell malignancies.  
 
Our data also pinpointed additional genes targeted by homozygous deletion in lymphoma. The 
NOXA gene was found inactivated by homozygous deletion and point mutation in different 
lymphoma cell lines. In addition, a missense mutation in the conserved BH3-domain was also 
identified. However, we did not identify similar mutations nor promoter methylation in lymphoma 
primary samples. Instead, we observed decreased NOXA protein expression in patient with non-
germinal diffuse large B-cell lymphoma, possibly reflecting the low expression of NOXA in their 
the normal cell counterpart. A recent report by Perez-Galan et al. indicated that in mantle cell 
lymphoma, NOXA depletion by RNA interference markedly decreased sensitivity to bortezomib, 
pointing to this protein as a key mediator between proteasome inhibition and mitochondrial 
depolarization in this lymphoma subtype. After incubation of different B-NHl lymphoma cell lines 
with different levels of NOXA with bortezomib, we did not observe differences in apoptosis, 
therefore not confirming the pivotal importance of NOXA in triggering proteasome-induced 
apoptosis in B-cell lymphomas other than mantle cell lymphoma.
30
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In summary, our combined approach has shown the extent to which DNA copy number variation 
influences the deregulation of gene expression in B-NHL. We demonstrate that array CGH 
combined with gene expression profiling may provide a rational for discovering tumor suppressor 
genes in regions of homozygous loss. These target genes show different genetic and epigenetic 
mechanisms of inactivation that substantially vary among the B-NHL subtypes. Similar screens 
for tumor suppressor genes can be extended to the analysis of other cancers. 
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TABLES 
 
Table 1: Molecular delineation of seven regions of homozygous genomic loss in B-NHL. 
Identification of putative tumor suppressor genes in B-NHL 
 a
 Map positions and cytogenetic locations are based on data available through the UCSC 
genome browser (May 2004 freeze). 
b 
Molecular delineation of regions of homozygous genomic loss was performed using array CGH,  
FISH and PCR of genomic DNA. For delineation of homozygous deletion borders, the more open 
positions of deleted BACs, have been used. The homozygous deletions of BIM and CDKN2C 
were demonstrated only by PCR. 
c 
In UPN1 cell line, partial homozygous deletion of BIM locus was demonstrated by PCR of 
genomic DNA. 
d 
REC1, Z138, K353, DOHH2, G452 and 380 cell lines showed only one deleted BAC, CTB-
65D18, sized 0.1 Mb (9p21.3). OZ and MD903 cell lines showed a region of deletion of 5.6 Mb 
(9p21.3-9p21.2), from CTB-65D18 to RP11-235F7. 
e 
In MD903 cell line, partial homozygous deletion of CTB-65D18 including the INK4/ARF locus  
was demonstrated by PCR of genomic DNA. 
f
 Homozygous deletion of BACs not included in the array was demonstrated by FISH. 
Table 1 
 
REGION OF 
CROMOSOME 
DELETION 
a
 
CELL LINES 
 
DELETED BACS
  
 
 
SIZE OF REGION OF 
DELETION
 
(Mb)
 a, b
 
 
 
PUTATIVE TARGET GENES WITHIN 
REGION OF DELETION  
1p32.3 HBL2, UPN1 - 0.006-0.690 INK4c/P18 
2q13 UPN1 
c
, SP49, SP53, JEKO1, Z-138, P32 - 0.043-0.751 BIM 
3p14.2 P32 RP11-94D19 0.2 FHIT 
4q35.1 ELIJAH RP11-203L17, RP11-159A22 0.25 ARGBP2, SNX25 
9p21.3-9p21.2 
d
 REC1, Z-138, OZ, Karpas 353, DOHH2, MD903
 
e
, Granta 452, 380 
CTB-65D18, RP11-33015, RP11-85J15,  
RP11-55P9, CTD-2170E19, RP11-235F7 
0.1-5.6 INK4/ARF 
16p13.13 K1106 RP11-396B14 
f
, RP11-49M6, RP11-547D14 
f
 0.6 SOCS1, LITAF 
18q21.32-18q21.33 ELIJAH RP11-12J12, RP11-40D15, RP11-15C15 2.0 NOXA 
 
 
 
 23
 
FIGURES 
FIGURE 1. Identification of homozygous deletion and expression of PIG7/LITAF 
A Real time RT-PCR analysis of PIG7/LITAF expression in samples from tonsil and spleen and in 
B-NHL cell lines (10 Mantle cell lymphoma cell lines; 11 diffuse large B cell lymphoma cell lines 
with t(14:18); 3 diffuse large B cell lymphoma cell lines lacking t(14;18) and 6 Burkitt lymphoma 
cell lines. Data shown are the relative gene expression levels normalized with GAPDH; bars 
indicate standard deviations. The results are derived from 3 independent experiments. MCL, 
mantle cell lymphoma, DLBCL, diffuse large B cell lymphoma, BL Burkitt lymphoma. 
B. Affymetrix oligonucleotide microarrays and Western blot analyses of PIG7/LITAF and BCL6 
 in mantle cell lymphoma cell lines. KHM10B cell line was used as a positive control for BCL6 
expression. 
C. Lymphochip cDNA microarrays and Western blot analyses of PIG7/LITAF and BCL6 in B-NHL 
cell lines of different origins. 
D. Immunohistochemistry analysis for PIG7/LITAF and BCL6 protein on tissue microarrays. In 
non-tumoral tissue samples (tonsils), PIG7/LITAF expression was cytoplasmatic and was shown 
to be expressed mostly in mantle, marginal and interfollicular lymphocytes whereas BCL6 was 
shown to be expressed in germinal center B cells. 
 
FIGURE 2. Promoter methylation of PIG7/LITAF. 
A. Methylation-specific PCR (MSP), Quantitative RT-PCR and Western blot analysis of 
PIG7/LITAF in RL and SCI1 cell lines before and after treatment with 4µM of 5-Aza-2’-
deoxycitine. The treatment with demethylating Aza restored PIG7/LITAF expression at the RNA 
and protein levels. In the QRT-PCR data analysis, gene expression levels were normalized with 
GAPDH as an internal control; bars indicate standard deviations. 
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B. Methylation-specific PCR (MSP) in primary biopsies of Burkitt lymphoma. M, methylated and 
U, unmethylated.  
C. Sequence analysis of the PIG7/LITAF promoter region after bisulfite modification. The black 
box indicates the methylated cytosine while the white box indicated the unmethylated cytosine in 
the dinucleotide CpG. C+ indicates methylated control 1: genomic sequence of PIG7/LITAF 
promoter region. 2: methylated sequence of the PIG7/LITAF promoter region after bisulfite 
modification and 3: unmethylated sequence of the PIG7/LITAF promoter region after bisulfite 
modification.  
 
FIGURE 3. Identification of homozygous deletion and promoter methylation of BIM 
A. Array CGH and genomic PCR studies of mantle cell lymphoma cell lines, showing interstitial 
homozygous deletion of BIM gene. In none of the cases, deletion of BUB1 gene was observed. 
B. Western blot analysis shows absence of expression of BIM protein in mantle cell lymphoma 
but also in Burkitt lymphoma cell lines and patient biopsies. 
C. Methylation of BIM promoter was frequently detected in Burkitt lymphoma cell lines and patient 
biopsies as well as in a subset of B-NHL from different origins, but not in mantle cell lymphoma. 
D. A detailed mapping of CpG-methylation of the promoter by bisulfite genomic sequencing 
confirmed previous data. 
E. BIM promoter methylation was correlated with loss of expression at the RNA and protein 
levels, and treatment with demethylating Aza restored BIM expression. 
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FIGURE 4. Inactivation of INK4c/P18 in mantle cell ylmphoma 
A. Array CGH studies and further screen with genomic PCR identified homozygous deletion of 
INK4c/P18 in two mantle cell lymphoma cell lines (UPN1 and HBL2) but not in the remaining B-
NHL cell lines. 
B. Affymetrix oligonucleotide microarrays performed in MCL cell lines of genes located in 1p36-
1p32.3 showed absence of CDKN2C expression in both cell lines.  
C. Mutation screening identified hemizygous loss and point mutation of INK4c/P18 at a critical 
splicing site of the remaining allele in JEKO1 cell line, which correlated with absence of P18 
expression. 
D. Western blot analysis revealed absence of protein expression in these three cell lines (UPN1, 
HBL2 and JEKO1) but also in the majority of other mantle cell lymphoma cell lines, and in three 
patients with mantle cell lymphoma, whereas INK4c/P18 protein expression was observed in the 
majority of other B-NHL subtypes. 
E. IHC on tissue microarrays revealed absence of expression of INK4c/P18 in mantle cell 
lymphoma with IGH ummutated status. 
 
FIGURE 5. Genomic and proteomic analysis of NOXA in B-NHL 
A. Array CGH analysis of ELIJAH cells shows homozygous deletion of chromosome band 
18q21.3. Within the region, NOXA gene expression shows null expression in the Lymphochip 
microarrays.  
B. Western blot and QRT-PCR analyses show expression variation of NOXA in different B-NHL 
cell lines; in ELIJAH, NOXA protein expression is absent according to DNA and RNA data.  
C. NOXA gene sequence changes in B-NHL cell lines; the nucleotide positions of NOXA are 
based on GenBank accession sequence NM_021127. Sequencing analysis of the non-deleted 
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alleles reveals a splice site mutation in Karpas 1106 and a misense mutation in the BH3-domain 
in Namalwa. 
D. Immunohistochemistry analysis for NOXA protein on tissue microarrays from 367 biopsies 
from patients with different B-NHL. In tonsils, NOXA was shown to be expressed only in a fraction 
of germinal center B-cells, whereas mantle, marginal and interfollicular lymphocytes were 
negative. In lymphoma samples, NOXA protein expression was restricted to diffuse large B-cell 
lymphoma (32 of 67, 48%) and in a subset of follicular lymphoma (20 of 103, 19%), whereas 
mantle cell lymphoma, splenic marginal zone lymphoma and B-cell chronic lymphocytic leukemia 
samples were mostly negative. 
E. Proteasome inhibitor, bortezomib (PS-341) in B-NHL cell lines with and without NOXA 
mutation. Cell lines were incubated for 24 and 48 h with increasing concentrations of bortezomib. 
Apoptosis was calculated by measuring phosphatidylserine (PS) externalisation as determined 
using Annexin V. The results correlated with loss of mitochondrial membrane potential (data not 
shown). Both the induction and rate of apoptosis was comparable between all the cell lines, 
irrespective of the presence of genetic alterations in NOXA. 
 
FIGURE 6. Homozygous deletion of 4q35.1.  
A. In the Elijah cell line, delineation of the deleted segment in 4q35.1 revealed a small deletion of 
251 kb between the potential candidates genes ARGBP2 and SNX25, both of which resulted 
truncated in a cryptic fusion between SNX25 exon 15 and ARGBP2 intron, and between ARGBP2 
exon 18 and SNX25 intron.  
B, C. Both genes splice to cryptic splice acceptor sites in the opposite transcriptional orientation. 
As a consequence of the deletion, ARGBP2 loses a crucial COOH terminal domain that may 
interfere with its binding to CBL and SNX25 also results in the truncation of the COOH terminal 
domain. Deletion of ALP gene, mapped between ARGBP2 and SNX25, is also detected. 
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D. Truncated SNX25 mRNA is expressed using RT-PCR.  
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SUPPLEMENTAL WEB TABLES  
 
SUPPLEMENTAL TABLE S1. Primers for QRT-PCR, sequence analysis and MSP. Primers 
and QRT-PCR measurement of CDK6 and NOXA genes in the B-NHL cell lines, and primers for 
genomic sequencing and methylation analysis using MSP for PIG7/LITAF, BIM, INK4c/P18 and 
NOXA are shown.  
 
SUPPLEMENTAL TABLE S2. Full karyotype and standard CGH description of 25 B-NHLcell 
lines. We performed genome-wide scanning for DNA copy number changes in 48 B-NHL cell 
lines using an array CGH method that covers the genome with a 1.4 Mb resolution (Figure 1). To 
assess sensitivity and resolution, array CGH patterns were compared to those of standard CGH 
to chromosomes (s-CGH) and to the cytogenetic analysis in 25 selected cell lines. On average, 
each cell line displayed 20 genomic changes in array CGH analysis (range, 4-35), comprising 
roughly equal numbers of gains and losses. In the 25 selected cell lines, s-CGH and cytogenetic 
analysis revealed a lower number of aberrations than in array CGH studies: mean number of 
abnormalities per case were 13 (range 1-25) and 12 (range, 2-20) in s-CGH and G-banding 
studies, respectively. Of the total of 70 genomic amplifications revealed by array CGH in the 25 
cell lines, only 22 (31%) were detected by s-CGH. Similarly, among 230 genomic losses detected 
by array CGH, only 95 (41%) were revealed by s-CGH. Thus, array CGH provided a more 
accurate quantitative and qualitative portrait of the DNA copy number changes in the B-NHL cell 
lines. To evaluate reproducibility of array CGH experiments, same aliquots from SCI1, PR1, OCI-
Ly8 and Z138 cell lines were analyzed twice. In the comparative analysis, only 14 clone pairs 
(range 4-33) from each of the paired tumors (representing the 0,7% of the probes that were 
successfully hybridized) from the different array CGH experiments showed discordant values 
(defined as differences in log2 value exceeding 0,3). In summary, array CGH was more sensitive 
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than conventional CGH, and was a highly reproducible method for the scanning of lymphoma 
genomes.  
 
SUPPLEMENTAL TABLE S3. Representation of amplification sites and genes targeted with 
elevated expression in B-NHL. 
a
 Map positions and cytogenetic locations are based on data available through the University of 
California Santa Cruz genome browser   (May 2004 freeze). 
b
 For amplicon borders, the more 
extern positions of amplified clones has been used.  
c
 Because abnormal clones that delineated 
the amplicon borders have been excluded in the May 2004 freeze of the UCSC genome browser, 
the closest positions of neighboring unamplified clones have been used. 
d 
Candidate genes with 
elevated expression are mapped to amplified regions delineated by the closest positions of 
neighboring unamplified clones.  
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SUPPLEMENTAL FIGURES 
 
SUPPLEMENTAL FIGURE S1. Genome-wide array CGH and cDNA microarray analyses of 
B-NHL.  
Genome-wide DNA and RNA copy number variation in the SSK-41 cell line using array CGH (A) 
and gene expression profiling (B) across the genome; probes were ordered according to their 
cytogenetic position from 1p telomere to Xq telomere. Individual amplifications of 3q27-q29, 
7q21-q22 and 18q21, and genomic deletion of 11p13, were confirmed, as shown, using s-CGH, 
FISH and color cytogenetic analyses. The upper inset shows the partial s-CGH and array CGH 
analyses of the SSK41 cell line, demonstrating amplification of 7q21-q22 involving CDK6 gene, 
which also showed deregulated expression in gene expression analysis. Cytogenetic analysis 
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showed a der(7)t(7;15)(q21;q15), +der(7)t(7;11;15)(q21;q21-q22;q15), del(10)(p12), 
+der(10)t(7;10)(q10;p10). FISH studies using a BAC probe containing the gene showed CDK6 
amplification in the SSK41 cell line. Western blot analyses revealed CDK6 over-expression in 
SSK41 cell line as well in Karpas 1718, both derived from patients with marginal zone lymphoma. 
Other cell lines with gain of 7q derived from other B-NHL subtypes did not show elevated 
expression of CDK6.  
We performed genome-wide scanning for DNA copy number changes in 48 B-NHL cell lines 
using high-resolution array CGH. To assess sensitivity and resolution, array CGH patterns were 
compared to those of standard CGH (s-CGH) and to the cytogenetic analysis in 25 selected cell 
lines. On average, each cell line displayed 20 genomic changes in array CGH analysis (range, 4-
35), comprising roughly equal numbers of gains and losses. s-CGH and cytogenetic analysis 
revealed a lower number of aberrations than array CGH: mean number of abnormalities per cell 
line were 13 (range 1-25) and 12 (range, 2-20) in s-CGH and G-banding studies, respectively. Of 
the total of 70 genomic amplifications revealed by array CGH in 25 cell lines, only 22 (31%) were 
detected by s-CGH. Similarly, among 230 genomic losses detected by array CGH in 25 cell lines, 
only 95 (41%) were revealed by s-CGH. These data indicate that array CGH provided a more 
accurate portrait of the DNA copy number changes in the B-NHL cell lines. To evaluate 
reproducibility of array CGH, the same aliquots from SCI1, PR1, OCI-Ly8 and Z138 cell lines 
were analyzed in duplicate. Only 14 clone pairs (range 4-33) from each of the paired tumors 
(representing the 0,7% of the probes that were successfully hybridized) from the different array 
CGH experiments showed discordant values (defined as differences in log2 value exceeding 0,3), 
confirming the reproducibility of the array CGH method.  
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SUPPLEMENTAL FIGURE S2. Array CGH analysis of the different B-NHL subtypes 
Left, array CGH profile of different B-NHL subgroups. DLBCL indicates diffuse large B-cell 
lymphoma; MCL,  mantle cell lymphoma; BL, Burkitt lymphoma; MZL, marginal zone lymphoma 
and PMBCL, primary mediastinal B-cell lymphoma. Right, array CGH profiles show genomic 
alterations that are associated with particular B-NHL subgroups: deletion of chromosome 1p21.2 
only in MCL; gain of 1q21.2-q25.1 in BL; gains of 8q13-q21 and 8q24.2 (MYC locus) in DLBCL 
with the t(14;18)(q32;q21) and deletion of 9p21.3 (INK4/ARF locus) in MCL. Genomic gains are 
shown in red, genomic losses in green and regions with normal DNA copy number in black.  
We investigated the association between specific genomic aberrations and the different B-NHL 
subtypes. The deletion of chromosome 1p21.2 was the only locus observed in only one B-NHL 
category, namely mantle cell lymphoma, but not in other subgroups (42% vs 0%; p=0,0005) 
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(Supplemental Figure S2). Some other genomic changes were correlated with the different B-
NHL subgroups. These included the deletion of chromosome bands 9p21.3 at INK4/ARF locus 
(75% vs 25%; p=0,003) and 2q13-2q21.2 at BIM locus (33% vs 8%; p= 0,05) and the gain of 
3q13.33-q21.3 (33% vs 3%; p=0.01) in mantle cell lymphoma; the gain of 8q24.21 (MYC locus) 
(73% vs 27%; p=0,004) and 11p15.2-p15.4 (33% vs 9%; p=0,05) in diffuse large B-cell lymphoma 
with the t(14;18)(q32:q21) translocation; the gain of 13q14.11 in diffuse large B-cell lymphoma 
without the t(14;18)(q32;q21) translocation (50% vs 12%; p=0,05) and the gain of 1q21.2-q23.3 
(64% vs 22%; p=0,01) and the deletion of 17p13.1 involving P53 (55% vs 22%; p=0,04) in Burkitt 
lymphoma. Therefore, regional genomic gains and losses showed a different distribution pattern 
among the B-NHL subtypes.   
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SUPPLEMENTAL FIGURE S3.  
Identification of targeted oncogenes in B-NHL 
A. Amplification and over-expression of CDK6 in marginal zone lymphoma cell line SSK41. 
Complementary FISH, color cytogenetic and Western blot analyses are shown.  
B. Amplification of different chromosome 13q segments in SSK41 (left) and MD903 (right) cell 
lines identified numerous genes targeted at the RNA level. 
C. Amplification of 6p21.2 incolving PIM1 in the JEKO1 mantle cell lymphoma cell line. Over-
expresison of PIM1 was detected in Lymphchip microarrays. In addition, we searched for PIM1 
expression in 11 mantle cell lymphoma cell lines using Affymetrix oligonucleotide microarrays, 
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being only JEKO1 the one with 6p amplicon. A number of genes across 6p21.2 showed elevated 
expression in JEKO1 vs. the remaining cell lines. Among them, PIM1 presented higher differential 
expression at the RNA level.  
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